Letairis (Ambrisentan) Patent Expiration, LOE Window & CMS Spending
Letairis (Ambrisentan) by Gilead Sciences: FDA Orange Book LOE 2031-10-14, 7 AB generics, $120.2M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N022081 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-10-14 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 7 |
| 2024 CMS Total Public Spend | $120.2M |
| 2024 Medicare Part D Spend | $82.7M |
| 2024 Medicaid Spend | $37.5M |
| Reported Wholesale Price Change (CA SB 17) | 16 WAC filings (max 22.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.